Articles
All 404 articles from Source GLP-1,, newest first. Search, filter by topic, or sort to find the one you need.
Why an Authentic-Looking Medicine Box Cannot Verify an Online Shipment
Convincing carton design is easy to reproduce, and photographic similarity is not authentication. Learn the practical checks, evidence limits and next quest
Why an Authentic-Looking Medicine Box Cannot Verify an Online Shipment
Convincing carton design is easy to reproduce, and photographic similarity is not authentication. Learn the practical checks, evidence limits and next quest
How to Verify a Compounding Pharmacy License, Step by Step
Step-by-step: verify a compounding pharmacy's license with its state board via NABP, check FDA's 503B outsourcing facility list, and spot red flags.
USP 797 Explained: The Sterile Standard Behind Compounded GLP-1s
What USP requires for compounded semaglutide and tirzepatide shots: categories, beyond-use dates, sterility and endotoxin testing, enforcement.
Sublingual Semaglutide Drops: What the Absorption Evidence Shows
No sublingual semaglutide is FDA-approved. FDA labels show even the approved pill absorbs only 0.4% to 2%. Here's what that means for drops and troches.
ATTAIN-MAINTAIN: Switching From GLP-1 Injections to Orforglipron
ATTAIN-MAINTAIN, read closely: how much weight people kept after switching from Wegovy or Zepbound to an orforglipron pill, and what the trial can't tell you.
Liraglutide Goes Generic: What Generic Victoza and Saxenda Mean
Generic liraglutide explained: when generic Victoza and Saxenda launched, who makes them, verified prices, and why the two generics aren't interchangeable.
MariTide Monthly Injection: Phase 2 Data and MARITIME Phase 3 Status
MariTide (maridebart cafraglutide) Phase 2 results, the vomiting issue, and every MARITIME Phase 3 trial with enrollment and dates, as of October 2026.
Your GLP-1 Platform Changed Pharmacies: Which Records Should Follow You?
A switch in dispensing pharmacy may alter concentration, device, instructions, shipping, and refills. Learn the practical checks, evidence limits and next q
Why 'Research Use Only' Semaglutide Is Not a Substitute for a Prescription
“Research use only” chemicals are not approved consumer medications. Learn the practical checks, evidence limits and next questions before making a GLP-1 de
Who Is Responsible After a GLP-1 Adverse Reaction: Platform or Prescriber?
The platform, prescriber, pharmacy, and manufacturer have different roles. Learn the practical checks, evidence limits and next questions before making a GL
When the Pharmacy Name Appears Only After Checkout: What to Ask First
A seller that conceals the pharmacy until payment removes an important independent check. Learn the practical checks, evidence limits and next questions bef
The Privacy Trail: Where Your Medical Data Go After a GLP-1 Online Intake
Medical-intake responses may travel through scheduling, payment, analytics, telehealth, and pharmacy systems. Learn the practical checks, evidence limits an
The Milligram-Milliliter-Units Trap in Online Injectable Medication Ads
Milligrams describe drug mass, milliliters describe liquid volume, and syringe units describe a mark on a particular syringe. Learn the practical checks, ev
The GLP-1 Chain-of-Custody Test: What Should Happen Before a Package Ships?
A safe shipment should be traceable through prescribing, fulfillment, labeling, and delivery. Learn the practical checks, evidence limits and next questions
The Fake Clinical-Trial Screenshot Test: Five Ways to Check an Original Study
A screenshot can crop out trial failures, change the unit on an axis, or omit the comparator. Learn the practical checks, evidence limits and next questions
The Ro, Hims, LifeMD, WeightWatchers Partnership Map
Complete map of the authorized telehealth partnerships for Wegovy and Zepbound distribution.
The 'Clinically Proven' GLP-1 Advertisement: Which Product Did the Trial Test?
“Clinically proven” sometimes borrows research from a different product, dose, device, or population. Learn the practical checks, evidence limits and next q
The Clinical Trial Number in a Weight-Loss Ad: Find Its Real Primary Endpoint
Trial headlines often feature the largest relative number, not the prespecified primary outcome. Learn the practical checks, evidence limits and next questi
Semaglutide vs Tirzepatide: Which One Should You Pick?
Head-to-head comparison of semaglutide and tirzepatide. Efficacy, side effects, cost, and who each medication works best for.
The Barcode on a GLP-1 Box: What an NDC Number Can and Cannot Prove
A number printed under a barcode can be looked up in the FDA NDC Directory, but an entry proves neither approval nor that the particular box in your hand is
If a Trial Uses a Surrogate Marker, What Did It Actually Prove About Health?
Surrogate endpoints such as laboratory markers can support biological mechanisms without proving that patients live longer or feel better. Learn the practic
Oral Wegovy at 5 Months: What the Real-World Data Shows
Oral Wegovy launched January 2026 at $149/month. Five months in, here
GLP-1 Discontinuation: What Happens When You Stop Taking the Medication
STEP 1 extension data shows most patients regain weight after stopping semaglutide. Here
How Long Do GLP-1 Medications Actually Last? Complete Shelf Life Guide
Compounded semaglutide lasts 28-90 days. Brand-name Ozempic: 24 months. Oral Wegovy: no refrigeration needed. A sourced storage and shelf life reference.
GLP-1 Products With Similar Names: How to Check the Active Ingredient and Label
Drug names can be similar while their active ingredients, delivery systems, indications, and dosing schedules differ. Learn the practical checks, evidence l
'FDA Registered' Is Not 'FDA Approved': A GLP-1 Seller Claim Decoder
FDA registration, FDA listing, and FDA approval describe different regulatory actions. Learn the practical checks, evidence limits and next questions before
Does a GLP-1 Subscription Give You a Named Clinician or Just a Support Inbox?
Unlimited messaging is not the same as accountable clinical follow-up. Learn the practical checks, evidence limits and next questions before making a GLP-1
Can You Trace an Online GLP-1 Prescription From Prescriber to Pharmacy?
Trace three handoffs: who made the medical decision, who transmitted the prescription, and which licensed pharmacy received it. Learn the practical checks,
An Online GLP-1 Seller Displays a Batch Number: Can You Verify It Independently?
A displayed batch or lot number is a starting point for the dispensing pharmacy to investigate, not a public guarantee of origin. Learn the practical checks
GobyMeds Review: $99/Month Semaglutide With No Membership Fees
GobyMeds offers compounded semaglutide from $99/month and tirzepatide from $133/month with no membership, free consultation, and free overnight shipping. Full 2026 review.
GLP-1 vs Bariatric Surgery: Comparing Weight Loss, Cost & Recovery in 2026
How does GLP-1 medication compare to gastric bypass and sleeve gastrectomy? We compared weight loss outcomes, costs, risks, recovery time, and long-term data.
Compounded GLP-1 Pricing Map: What Every Provider Charges (May 2026)
We compiled compounded and brand-name GLP-1 pricing from verified provider websites. Every option ranked from cheapest to most expensive.
Is $1,000/Month Worth It?
An honest analysis of GLP-1 medication costs vs benefits. What the health economics research says about value.
GLP-1 Insurance & Cost Guide
Strategies for getting GLP-1 medications covered by insurance, manufacturer savings programs, and alternative options when coverage fails.
Sprout Health GLP-1 Review: Cost, Medications & What to Expect in 2026
Sprout Health offers compounded semaglutide at $249/month and tirzepatide at $299/month with locked pricing at any dose. Full 2026 review covering cost, process, and legitimacy.
Retail Pharmacy GLP-1 Pricing: Costco, Walmart, CVS
Complete reference on retail pharmacy cash-pay pricing for GLP-1 medications in 2026.
PBM Rebate Economics: Why Your Copay Isn't the List Price
Explainer on PBM rebate economics and how they affect GLP-1 copays vs cash-pay pricing.
GLP-1 Cost in 2026: Every Option from $50 to $1,349 per Month
Complete GLP-1 pricing guide for 2026: Medicare Bridge at $50/mo, oral Wegovy at $149, compounded options, insurance, and manufacturer savings programs. Every price sourced.
The Medicare Price Negotiation: Unpacking the 71% Ozempic Discount
Full breakdown of the Medicare 71% Ozempic discount and what it means for 2027 GLP-1 access.
International GLP-1 Price Arbitrage in 2026
International GLP-1 price arbitrage analysis — what channels remain economically meaningful in 2026.
The $349 Wegovy Price Cut: A Full Pricing Timeline
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
GLP-1 Pricing Exposed: From API Cost to Your Pharmacy Bill
The raw ingredient for a month of Ozempic costs under $50. So why does a prescription cost $1,000+? Breaking down the GLP-1 pricing chain with sources.
How Much Does GLP-1 Actually Cost? (2025 Price Breakdown)
Some examples and provider price illustrations in this article are estimates, not guaranteed checkout quotes.
A GLP-1 Site Promises Same-Day Approval: What Should a Real Evaluation Include?
Speed is not the same as a medical evaluation. Learn the practical checks, evidence limits and next questions before making a GLP-1 decision.
A Drug-Interaction Checklist Is More Important Than a Two-Minute Weight-Loss Quiz
A two-minute intake can be a gateway, but medicine decisions require more than eligibility marketing. Learn the practical checks, evidence limits and next q
Zepbound Vial Pricing Decoded: Every Dose, Every Channel
Complete decoded breakdown of Zepbound vial pricing by dose, channel, and commercial structure.
The Yale Secret Shopper Study, In Full: Methodology, Findings, and Limitations
JAMA Network Open published findings from investigators who submitted intake forms to 49 telehealth GLP-1 platforms. 45 prescribed. Two-thirds with no docu
Tirzepatide 101: The Complete Beginner's Guide
Everything you need to know about tirzepatide (Mounjaro/Zepbound). How it works, dosing, what to expect, and why it
Weight Regain After Stopping GLP-1s: What the Data Actually Shows
What happens when you stop semaglutide or tirzepatide? We analyze the STEP 1 extension, SURMOUNT-4, and real-world data on weight regain and prevention strategies.
Sulfur Burps Explained: The GI Science Behind GLP-1 Side Effects
Why do Ozempic and Wegovy cause rotten egg burps? The science of delayed gastric emptying, hydrogen sulfide, and evidence-based relief strategies.
SYNERGY-NASH: Tirzepatide's Liver Disease Breakthrough
Deep evidence review of the SYNERGY-NASH trial of tirzepatide for MASH/NASH liver disease.
TrumpRx Explained: The Government Portal Reshaping GLP-1 Access
Complete explainer on the TrumpRx federal drug portal and what it means for GLP-1 access.
SURMOUNT-OSA: Tirzepatide for Obstructive Sleep Apnea — Complete Trial Data
SURMOUNT-OSA: Tirzepatide for Obstructive Sleep Apnea — Complete Trial Data
How Much Is Tirzepatide on Sprout Health? 2026 Pricing Breakdown
Some examples and provider price illustrations in this article are estimates, not guaranteed checkout quotes.
State Attorneys General vs. GLP-1 Telehealth: Active Investigations
Active state AG investigations into GLP-1 telehealth companies and what they mean for the industry.
STEP HFpEF: GLP-1s for Obesity-Related Heart Failure
Evidence review of the STEP HFpEF trial of semaglutide for heart failure with preserved ejection fraction.
The STEP Program: Every Semaglutide Weight-Loss Trial
Evidence review of the complete STEP clinical trial program for semaglutide weight management.
SURPASS-CVOT: Tirzepatide's Diabetic Heart Disease Data
Deep evidence review of the SURPASS-CVOT trial of tirzepatide for diabetic cardiovascular disease.
Wegovy HD 7.2mg: The Data Behind the Strongest Semaglutide Dose
FDA approved semaglutide 7.2mg on May 13, 2026. STEP UP trial: 20.7% weight loss, 1 in 3 achieving 25%+. The sourced data breakdown.
Weight Maintenance After GLP-1: What the 2026 Data Actually Shows
Smart step-down protocols preserve most weight loss. The Lancet 2026 maintenance data explained.
Tirzepatide vs. Semaglutide: The Complete Head-to-Head Comparison
A comprehensive comparison of Mounjaro/Zepbound (tirzepatide) vs Ozempic/Wegovy (semaglutide). Weight loss data, side effects, mechanisms, and which might work better for you.
Should You Stock Up on Compounded GLP-1s Before the June 29 Deadline?
The FDA proposed banning 503B GLP-1 compounding on April 30. The comment period closes June 29. Patients are asking: should I order extra now? Here's what the data says about shelf life…
Survodutide: Boehringer's GLP-1/Glucagon Dual Agonist Improved MASH in 83% of Patients
Survodutide Phase 2 NEJM data: 83% MASH improvement, 87% liver fat reduction, 64.5% fibrosis improvement. Glucagon mechanism explained. Phase 3 trials for obesity and liver disease underway.
SURMOUNT-5: Tirzepatide vs. Semaglutide Head-to-Head — The Complete Data
The first direct comparison trial: tirzepatide lost 20.2% vs. semaglutide
Stanford's Muscle Discovery: A Potential Solution for GLP-1 Patients
Stanford identifies a drug that may help preserve muscle during GLP-1 weight loss. The PNAS June 2026 study.
State-by-State GLP-1 Prescribing Rules: Where Telehealth Hits Legal Walls in 2026
State-by-State GLP-1 Prescribing Rules: Where Telehealth Hits Legal Walls in 2026
STEP-HFpEF: Semaglutide for Heart Failure With Preserved Ejection Fraction
STEP-HFpEF: Semaglutide for Heart Failure With Preserved Ejection Fraction
Weight Regain After Stopping GLP-1s: What STEP 1 Extension and Real-World Data Show
Weight Regain After Stopping GLP-1s: What STEP 1 Extension and Real-World Data Show
Survodutide Phase 3 Results in NASH/MASH: A Primary Source Breakdown
Boehringer Ingelheim's GLP-1/glucagon dual agonist met its primary MASH endpoint: 54% resolution vs. 16% placebo. The benefit-risk profile, the glucagon receptor mechanism question, and…
The UC San Diego Semaglutide Epigenetic Aging Study, Explained
A Nature Aging publication reported a 2.4-year reduction in GrimAge2 epigenetic clock scores after 52 weeks of semaglutide. What epigenetic clocks actually
SUMMIT Trial Dissected: Tirzepatide for Heart Failure With Preserved Ejection Fraction
SUMMIT showed tirzepatide improved exercise capacity and reduced heart failure events in HFpEF patients with obesity. Full results and implications sourced.
SURMOUNT-5 Dissected: The One Real Sema vs. Tirz Head-to-Head, Honestly Read
SURMOUNT-5 is the only direct head-to-head RCT comparing semaglutide 2.4mg vs tirzepatide 15mg. Here
Semaglutide 101: The Complete Beginner's Guide
Everything you need to know about semaglutide. How it works, what to expect, dosing, side effects, and results from clinical trials.
Retatrutide: The Triple Agonist Approaching Bariatric Surgery Results
Eli Lilly's next-generation drug achieves 28.7% weight loss in Phase 3—the first medication to rival gastric sleeve surgery.
Semaglutide vs. Tirzepatide: What the Head-to-Head Data Actually Shows
SURMOUNT-5 trial data compared: tirzepatide achieved 20.2% weight loss vs semaglutide
Retatrutide Phase 2: The 24% Weight Loss Molecule
Evidence review of retatrutide phase 2 data and the TRIUMPH phase 3 program.
SELECT Trial Five-Year Follow-Up: Cardiovascular Outcomes Data
Deep evidence review of the SELECT cardiovascular outcomes trial and its extended follow-up.
The Patent Cliff: When Generic Semaglutide Actually Arrives
Full timeline for when generic semaglutide actually arrives at U.S. retail pharmacies.
Retatrutide: The Triple Agonist That Hit 24.2% Weight Loss in Phase 2
Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data: 24.2% body weight loss at 48 weeks, 86% achieved normal liver fat. Here
Real-World GLP-1 Adherence: Why 50% of Patients Quit Within a Year
Real-World GLP-1 Adherence: Why 50% of Patients Quit Within a Year
Real-World Evidence Registries: What Post-Marketing GLP-1 Data Is Telling Us
Trial data was generated under controlled conditions. Claims databases, EHR networks, and FAERS are telling a different story: 68% real-world adherence vs.
Real-World Evidence vs. RCTs: Why GLP-1 Effect Sizes Shrink Outside Trials
Clinical trials show 15-25% weight loss. Real-world data shows 5-12%. The gap isn
Semaglutide 7.2mg: The Higher-Dose STEP-UP Data Reviewed
Semaglutide 7.2mg (3x the approved Wegovy dose) showed 20.7% weight loss in STEP-UP 1. Full efficacy data, safety signals, and timeline to approval.
The SOLSTICE Trial Read-Out: Elecoglipron's Full Efficacy and Safety Tables
Pfizer's oral GLP-1 receptor agonist elecoglipron (PF-07081532) reported Phase 2b SOLSTICE trial results in mid-2026. Here are the full efficacy and safety tables, annotated.
"Ozempic Penis" — What Urologists Actually Say
Men on semaglutide report their penis "got bigger." We reviewed the medical literature and talked to the experts. Here's what the evidence shows.
Oral vs Injectable Semaglutide: The Bioavailability Data
Oral semaglutide (Rybelsus) has 0.4-1% bioavailability vs. 89% for injectable. Here
"Ozempic Face" — Dermatologists Explain the Aging Effect
Rapid GLP-1 weight loss can cause facial volume loss, sagging skin, and premature aging. Here
Does Ozempic Kill Your Alcohol Cravings? (Source: Yes)
Randomized trial data confirms semaglutide reduces alcohol consumption. The neuroscience of why GLP-1 drugs decrease drinking—verified with sources.
Can You Get Ozempic Without a Prescription? (Source: No)
Semaglutide (Ozempic, Wegovy) is a prescription-only medication in the United States. Here's why, and how to access it legitimately.
"Ozempic Dreams" — Why Users Report Bizarre, Vivid Dreams
Thousands report strange, vivid dreams on semaglutide. Shopping with Clint Eastwood, robbing museums with celebrities. Here
Orforglipron: The Oral GLP-1 That Could Democratize Weight Loss
Wegovy efficacy in a daily pill. No fasting. No injections. Projected $200-350/month. Why this might be the most disruptive drug in the pipeline.
The Orforglipron ACHIEVE Trials: Oral GLP-1 Efficacy
Orforglipron is Eli Lilly's oral non-peptide GLP-1. Here's what the ACHIEVE and ATTAIN trials show and when it's likely to launch.
Orforglipron: The Next Oral GLP-1 in the Pipeline
While oral Wegovy requires an empty stomach and 30-minute wait, Eli Lilly's orforglipron can be taken with or without food. Phase 3 data is in, and an FDA decision is expected by end of…
Pemvidutide: The GLP-1/Glucagon Drug Targeting Both Weight and Liver Disease
Altimmune's pemvidutide occupies a narrower niche than most GLP-1 pipeline drugs: it's engineered specifically to treat the intersection of obesity and metabolic liver disease. Like…
Oral Semaglutide: The OASIS Trial Program That Made the GLP-1 Pill Real
The FDA approved oral Wegovy in December 2025 based on OASIS 4 data: 16.6% weight loss at 64 weeks. Complete trial results, comparisons to injectable, and what it means for patients.
Pediatric GLP-1 Prescribing: A Review of Current Clinical Trial Data
The STEP TEENS trial found semaglutide reduced BMI by 16.1% in adolescents at 68 weeks. Tirzepatide
Oral Semaglutide 25mg and 50mg: OASIS Trials Compiled
Oral semaglutide at 25mg and 50mg delivers weight loss approaching injectable semaglutide 2.4mg — a milestone for patients who prefer pills over injections. OASIS is the Phase 3 program…
Prior Authorization Approval Rates for GLP-1s: What the Data Shows by Insurer
Prior authorization for GLP-1 weight loss medications is denied 30-60% of the time depending on insurer. Published data on approval rates, appeal success, and workarounds.
How to Get GLP-1 Through Telehealth (Step-by-Step)
The exact process from quiz to delivery. How telehealth GLP-1 prescriptions work, what to expect, and how long it takes.
Injectable vs Oral vs Sublingual: Which Form is Right for You?
GLP-1 delivery methods compared. Needles vs pills vs drops. Pros, cons, and which format fits your lifestyle.
Next-Gen GLP-1s: The Retatrutide, Amycretin & Orforglipron Data
Retatrutide delivers 28.7% weight loss in Phase 3. Amycretin hits 22%. Orforglipron offers needle-free daily pill. Complete trial data on what
Novo Nordisk's 111+ Trademark Lawsuits Against Compounders
Novo Nordisk has filed 111+ lawsuits against compounding pharmacies and telehealth companies. Track every case, outcome, and what it means for compounded semaglutide.
When to Stop or Pause Your GLP-1 Medication
Complete guide on when to pause or stop semaglutide and tirzepatide. Covers pre-surgery protocols, pregnancy planning, adverse events, weight plateaus, and what happens when you stop.
HRSA 340B and GLP-1s: The Hospital Pricing Loophole
How the HRSA 340B program creates a hidden GLP-1 pricing channel through hospitals and FQHCs.
The Novo–Hims Settlement: How the Compounded Copycat War Ended
Inside the March 9, 2026 Novo Nordisk-Hims & Hers settlement that ended the compounded semaglutide war.
2026 Revenue Forecasts: Novo vs. Lilly by the Numbers
2026 GLP-1 revenue forecasts for Novo Nordisk and Eli Lilly, with Wegovy and Zepbound breakdowns.
SEC Filings Reveal: What Novo and Lilly Told Investors About 2026 Pricing
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
Who Should NOT Take GLP-1s
These medications aren't for everyone. Absolute contraindications, cautions, and situations where GLP-1s may not be appropriate.
NIH Maps How Semaglutide Works in the Brain
Nature Metabolism study reveals the exact neuronal pathway — a breakthrough for more precise GLP-1 therapy.
The Oral GLP-1 Era Has Arrived: A Research-Based Timeline
From Rybelsus (2019) to Foundayo (2026): how oral GLP-1 development reached the tipping point.
International GLP-1 Pricing: Why Americans Pay 10× More
Wegovy costs $1,349/month in the US, under $200 in Germany, and as little as $40 in India. Here
Medicare BALANCE Model: What Changes for GLP-1 Coverage
CMS announced the BALANCE Model in December 2025 to expand GLP-1 access through Medicare and Medicaid. Copays capped at $50/month. Medicaid launch expected May 2026, Medicare Part D January…
What the JMIR Clinical Support Gap Study Actually Found About Lean Mass Loss
A May 2026 retrospective cohort study in J Med Internet Res found patients receiving GLP-1 medications through telehealth without nutritional support lost
Medicare GLP-1 Bridge: The $50/Month Program Fact-Checked
CMS fact-checked: eligible drugs, qualifying conditions, enrollment process, timeline for July 2026 launch.
Novo Nordisk vs. Eli Lilly: The $200 Billion GLP-1 Market War in Charts
Novo Nordisk vs. Eli Lilly: The $200 Billion GLP-1 Market War in Charts
The Lancet 2026: GLP-1 Medications Protect Multiple Organ Systems
A landmark Lancet review confirms GLP-1s have direct protective effects on hearts, kidneys, livers, and brains.
Health Equity and GLP-1 Access: A Review of the Disparities Literature
Among eligible patients with T2D and obesity, GLP-1 prescribing rates: 18.4% for non-Hispanic White patients, 9.6% for non-Hispanic Black patients. A syste
The Medicare GLP-1 Bridge, Explained: Eligibility, Structure, and Sunset Date
The CMS demonstration program launched July 1, 2026, creating the first Medicare pathway for GLP-1 obesity treatment. Eligibility requirements, cost-sharin
Muscle Preservation on GLP-1s: A Review of the Resistance Training Trial Data
GLP-1 users without exercise lose ~38% of weight loss as lean mass. The Lundgren 2021 RCT showed exercise + liraglutide reduced lean mass loss by 40% versu
GLP-1s and Alcohol Use Disorder: Every Human Trial Registered Through Mid-2026
Semaglutide and other GLP-1 receptor agonists reduce alcohol intake in animal models and real-world data. Here
GLP-1s & Testosterone: What the Studies Actually Show
Research shows GLP-1 medications can increase testosterone levels in men with obesity by 18% on average. Here
Why Food Tastes Different on GLP-1s
Why does food taste different on semaglutide? New research shows GLP-1 drugs actually change taste bud gene expression and brain response to sweetness.
The Plateau Problem: Why GLP-1 Weight Loss Stalls
Weight loss stopped on Ozempic? Research shows plateaus typically occur around 60-68 weeks. Here
The "Prozac Moment" for Addiction
Researchers are calling GLP-1 medications a potential paradigm shift for addiction treatment. What the 12+ clinical trials mean for the future of treating compulsive behaviors.
SURMOUNT-OSA: Tirzepatide Cuts Sleep Apnea Severity by Up to 63%
Tirzepatide dramatically reduced sleep apnea severity in obese patients, potentially offering an alternative to CPAP. NEJM results show up to 63% AHI reduction.
Switching GLP-1 Medications: When to Change and How to Do It
Complete guide to switching from semaglutide to tirzepatide or between GLP-1 providers: when to switch, dose conversion, avoiding gaps, and what to expect.
GLP-1s and Shopping Addiction: Anecdotes Meet Neuroscience
GLP-1 users report reduced compulsive shopping. No studies exist, but the dopamine science is intriguing. We separate anecdotes from theory.
Can GLP-1 Medications Help You Quit Smoking?
Can Ozempic help you quit smoking? We analyze the Annals of Internal Medicine study, active clinical trials, and the science behind GLP-1s and nicotine addiction.
Stopping GLP-1 Medications: What Actually Happens
What happens when you stop Ozempic or Zepbound? The STEP-1 extension data on weight regain, tapering strategies, and when you actually need to stop permanently.
GLP-1s and Thyroid Cancer: What the Black Box Warning Means
The facts on semaglutide, tirzepatide and thyroid cancer risk. Understanding the FDA Black Box Warning, rodent studies vs human data, and who should not take GLP-1 medications.
GLP-1s and Vision Loss: What the NAION Signal Means
What the research shows about semaglutide and NAION (nonarteritic anterior ischemic optic neuropathy). The JAMA study, FDA FAERS data, risk factors, and what you should watch for.
Zepbound Approved for Sleep Apnea: A Historic First
Tirzepatide becomes the first medication ever approved to treat obstructive sleep apnea. What the SURMOUNT-OSA trial showed and what it means for 30 million Americans.
GLP-1s and Smoking: The Unexpected Quit Aid
People are reporting they quit smoking on Ozempic without trying. The science behind GLP-1s and nicotine addiction, plus active clinical trials.
"Ozempic Killed My Shopping Addiction"
People report their urge to shop has vanished on GLP-1 medications. Why dopamine-driven retail therapy may be the latest
Side Effect Survival Guide
Practical, evidence-based strategies for managing nausea, constipation, and other common GLP-1 side effects. What works and what doesn
TikTok Myths Debunked
Separating fact from fiction on the most viral GLP-1 claims. What the science actually says about common Ozempic myths.
Traveling with GLP-1 Medications
How to travel with Ozempic, Wegovy, or Mounjaro. TSA rules, temperature storage, and international considerations.
GLP-1s vs Bariatric Surgery
Comparing GLP-1 medications to bariatric surgery. Outcomes, reversibility, costs, and how to decide which approach is right for you.
What to Eat on GLP-1 Medications
Practical nutrition guidance for Ozempic, Wegovy, and Mounjaro. What to eat, what to avoid, and how to maximize results while minimizing side effects.
What We Still Don't Know
An honest look at the unanswered questions about GLP-1 medications. What the long-term data is missing and what we
GLP-1s for Adults 75+: The Evidence Gap
Most clinical trials excluded patients over 75. Here's what we actually know, what we're extrapolating, and when GLP-1s may still be appropriate.
GLP-1s and Psoriasis: Can Weight Loss Clear Your Skin?
Emerging evidence that GLP-1 weight loss may improve psoriasis severity. The obesity-inflammation-psoriasis connection and what patients are reporting.
GLP-1s for Shift Workers: Timing Your Injections
When to inject Ozempic or Mounjaro with irregular work hours. Practical guidance for nurses, factory workers, and anyone with rotating or night shifts.
GLP-1 and Surgical Anesthesia: The Fasting Debate
GLP-1 drugs slow gastric emptying, raising concerns about aspiration during anesthesia. The ASA updated its guidelines in 2023. Here
GLP-1 Receptors: Where They Are in Your Body
These receptors are everywhere—brain, heart, kidneys, gut, pancreas, and more. Understanding their distribution explains why GLP-1 drugs have such wide-ranging effects.
Sulfur Burps on GLP-1s: Why They Happen and How to Stop Them
The dreaded sulfur burps on GLP-1 medications. Why they happen, foods that trigger them, and proven strategies to reduce or eliminate this embarrassing side effect.
Triple Agonism Explained: How Retatrutide Works
Retatrutide targets three receptors: GLP-1, GIP, and glucagon. How triple agonism could deliver even greater weight loss than current medications.
Your First Week on GLP-1s: A 7-Day Meal Plan
A practical 7-day meal plan for your first week on Ozempic, Wegovy, or Mounjaro. Nausea-friendly foods, protein priorities, and easy recipes.
GLP-1 Reviews: What Patients Actually Report About Weight Loss in 2026
Are GLP-1 medications legit? We reviewed the clinical trial data, real patient outcomes, and what to realistically expect from semaglutide and tirzepatide for weight loss.
GLP-1 Slow Responders: Why It's Not Working and What to Try Next
Not losing weight on GLP-1 medication? 10-15% of patients are slow or non-responders. Here
GLP-1 Research Highlights: The Best News From the First Half of 2026
Cancer prevention, muscle protection, oral options, Medicare coverage — the most encouraging GLP-1 research of 2026.
GLP-1 Receptor Biology: How These Drugs Actually Work at the Cellular Level
The endogenous GLP-1 hormone has a 90-second plasma half-life. The pharmaceutical versions extend this to a week through fatty acid binding. A rigorous pha
GLP-1 Muscle Loss: How Much Lean Mass Do Users Actually Lose?
Comprehensive analysis of body composition data from STEP, SURMOUNT, and SURPASS trials. What DXA and MRI studies reveal about semaglutide and tirzepatide effects on lean mass.
GLP-1s & Opioid Addiction: Penn State's Breakthrough Research
Can semaglutide reduce opioid cravings? Penn State researchers found a 40% reduction in cravings in early trials. Here
GLP-1s for MASH: Semaglutide Becomes Second FDA-Approved Treatment
Semaglutide received FDA approval for MASH in August 2025—the second drug ever approved for fatty liver disease. Phase 3 trial data, tirzepatide pipeline, and what it means.
GLP-1 Drugs Show Promise for Parkinson's Disease: What the Phase 2 Data Found
Lixisenatide stopped motor symptom progression in early Parkinson
Managing GLP-1 Nausea: What Actually Works
Complete guide to managing nausea on semaglutide and tirzepatide: why it happens, how long it lasts, foods that help, medications like Zofran, and when to call your doctor.
The Complete GLP-1 Pipeline: Every Drug in Development, Ranked
Complete guide to next-gen GLP-1 drugs: CagriSema, Amycretin, Survodutide, VK2735, and more. Efficacy rankings, mechanisms, timelines, and how they compare to current medications.
GLP-1s and Pancreatitis: What You Need to Know
The facts on semaglutide, tirzepatide and pancreatitis risk. Symptoms to watch for, who
GLP-1s and PCOS: A Promising Connection
How semaglutide and tirzepatide are helping women with PCOS. The connection between insulin resistance, weight loss, and hormonal balance.
The FLOW Trial: Semaglutide Protects Kidneys
The FLOW trial was stopped early because semaglutide worked so well for kidney disease. What the data shows and what it means for millions with CKD.
Month by Month: What to Expect
A realistic timeline of your GLP-1 journey. What happens month 1, month 3, month 6, and beyond. Setting proper expectations.
The Next Generation
What's coming after Ozempic and Mounjaro? The drugs in late-stage clinical trials that could define the next era of obesity treatment.
Ozempic vs Wegovy vs Mounjaro
Head-to-head comparison of the major GLP-1 medications. Differences in weight loss, mechanism, dosing, side effects, and cost.
Why Some People Don't Respond
10-15% of people don't get significant results from GLP-1 medications. The science behind non-response—and what to try next.
Protein Requirements on GLP-1s
Protein requirements while on Ozempic, Wegovy, or Mounjaro. How much to eat, best sources, and strategies for when appetite is low.
GLP-1 and MASLD/MASH: The Liver Disease Revolution Nobody's Talking About
Metabolic dysfunction-associated steatohepatitis (MASH) — formerly called NASH — affects an estimated 16 million Americans and is projected to become the leading cause of liver…
GLP-1 and Liver Health: Semaglutide's MASH Approval Explained
Semaglutide is FDA-approved for fatty liver disease. What the clinical data shows and who benefits.
GLP-1s and Menopause: Complete Hormonal Guide
Complete guide to GLP-1 medications during and after menopause. HRT compatibility, targeting visceral fat, bone health monitoring, and cardiovascular benefits for postmenopausal women.
Pediatric GLP-1 Trials: The Complete Data
Complete analysis of GLP-1 clinical trials in adolescents. STEP TEENS results, liraglutide pediatric data, and ongoing tirzepatide studies in children and teens.
GLP-1 Medications for Teens: What Parents Need to Know
FDA-approved GLP-1 medications for adolescents 12+. STEP TEENS trial data, safety considerations, and what the AAP recommends for childhood obesity treatment.
GLP-1s During Perimenopause: Navigating the Hormonal Shift
How Ozempic and Wegovy work during perimenopause. Addressing hormonal weight gain, interactions with HRT, and what the research shows for women 40-55.
GLP-1s After Bariatric Surgery: When It Makes Sense
Can you use Ozempic or Wegovy after gastric sleeve or bypass? Evidence on weight regain treatment, safety considerations, and which post-bariatric patients are candidates.
GLP-1 and PCOS: What the Clinical Evidence Shows
Polycystic ovary syndrome affects 10% of women. GLP-1 drugs improve insulin resistance, reduce androgens, restore ovulation, and produce weight loss. Here
Why Weekly Dosing Works: GLP-1 Pharmacokinetics Explained
How semaglutide and tirzepatide stay active for a week when natural GLP-1 lasts only minutes. The science of half-life, albumin binding, and steady-state levels.
Muscle Loss on GLP-1s: How Much Is Normal, and What Actually Prevents It
Muscle Loss on GLP-1s: How Much Is Normal, and What Actually Prevents It
GLP-1 and Kidney Protection: The FLOW Trial Data
The FLOW trial's results — and semaglutide's subsequent FDA approval for chronic kidney disease — represent one of the most significant expansions of GLP-1 indications. For the first time…
GLP-1 and Osteoarthritis: ADA 2026 Data Shows Real Pain Relief
Semaglutide significantly reduced knee pain in arthritis patients. Weight loss gives joints a second chance.
The GLP-1 Patent Cliff Timeline: When Biosimilars and Generics Actually Arrive
Semaglutide patents expire 2032-2035. Tirzepatide patents extend further. Here
Hair Loss on GLP-1s: Every Study Analyzed
Is GLP-1 hair loss real? We reviewed every FAERS analysis, cohort study, and dermatology paper. Here
Why First-Gen GLP-1s Failed for Addiction (And Semaglutide Might Succeed)
Exenatide and liraglutide trials for alcohol and cocaine showed mixed results. Why researchers think semaglutide
GLP-1 Drugs and Inflammation: What the Evidence Shows for Autoimmune Conditions
New data suggests GLP-1 drugs may reduce inflammation markers and autoimmune disease risk. Here
FLOW Trial: Semaglutide Reduces Kidney Disease Progression by 24%
The landmark FLOW trial showed semaglutide reduced major kidney events and death in diabetic kidney disease. Published in NEJM, stopped early for efficacy.
GLP-1s and Heart Failure: A Game-Changer for HFpEF
Semaglutide dramatically improved symptoms and quality of life in heart failure patients. What the STEP-HFpEF trial means for millions living with HFpEF.
GLP-1 Drug Interactions: What You Can & Can't Take Together
Complete guide to GLP-1 medication interactions with insulin, sulfonylureas, birth control, levothyroxine, warfarin, and alcohol. Based on FDA labels and 2025 ADA guidelines.
GLP-1 Insurance Coverage 2025: The Complete Navigation Guide
Navigate GLP-1 insurance in 2025: Medicare/Medicaid coverage by state, commercial plan restrictions, prior auth strategies, appeal tactics, and manufacturer savings programs up to…
GLP-1 Injection Technique: Sites, Rotation, and Pro Tips
Complete guide to injecting semaglutide and tirzepatide: best injection sites, rotation patterns, preparation steps, and techniques for reducing pain and anxiety.
GLP-1s and Gout: Can These Medications Lower Uric Acid?
GLP-1 medications may help gout by lowering uric acid levels. The obesity-gout connection, research on semaglutide and uric acid, and what patients report.
GLP-1s and Gambling: Anecdotes, Science, and Missing Data
Users report GLP-1s curb gambling and shopping urges. We analyze the anecdotal reports, dopamine science, and why no clinical trials exist yet.
GLP-1s and Gallbladder Problems: What You Should Know
Why rapid weight loss from semaglutide and tirzepatide increases gallstone risk. Symptoms to watch for, when to pause treatment, and whether you can restart after gallbladder surgery.
GLP-1s and Fatty Liver Disease: The MASH Revolution
Semaglutide shows remarkable results for MASH (fatty liver disease). What the ESSENCE trial found and why FDA granted Breakthrough Therapy designation.
GLP-1s and Gambling: The Compulsion Quieter
Reports of gambling urges disappearing on GLP-1 medications. The dopamine connection, viral stories, and what researchers think is happening.
What Is "Food Noise"?
Food noise is the constant mental chatter about eating. Here
Exercise on GLP-1 Medications
How to exercise while on Ozempic, Wegovy, or Mounjaro. Why resistance training is essential and how to optimize your workouts.
GLP-1 Medications for Adults 65+: Complete Guide
Evidence-based guide to Ozempic, Wegovy, and other GLP-1s for seniors. Clinical trial data on adults 65+, muscle loss prevention, and special considerations from the SELECT and FLOW trials.
The Gut-Brain Axis: How Your Gut Talks to Your Brain
GLP-1 is a key messenger between your gut and brain. Understanding this communication system explains appetite, satiety, food noise, and why these medications work.
Keto + GLP-1 Medications: What You Need to Know
Is combining a ketogenic diet with Ozempic or Mounjaro safe and effective? Potential benefits, risks, and practical considerations for keto on GLP-1 medications.
"Food Noise" Explained: The Science of Constant Hunger
The constant mental chatter about food that vanishes on GLP-1 medications. What causes food noise, why some brains are louder, and how semaglutide silences it.
GLP-1 Insurance Coverage: The 2026 State-by-State Landscape
Insurance coverage for GLP-1 weight loss drugs varies dramatically by state, employer, and plan type. Some states mandate coverage; many Medicaid programs still exclude anti-obesity…
When Do GLP-1 Generics Arrive? The Complete Patent Cliff Analysis
Semaglutide patents expire December 2031, tirzepatide January 2036. Generic liraglutide arrived in 2024. Full patent landscape, settlement details, biosimilar pathway, and international…
GLP-1 and Gallbladder Events: Quantifying the Risk
Rapid weight loss from any cause increases gallstone risk. GLP-1 drugs are no exception. Here
GLP-1 Drug Interactions: A Pharmacology Literature Review
Gastric emptying delayed ~40%. The downstream effect on oral contraceptive Cmax, levothyroxine absorption timing, warfarin INR stability, and the weight-lo
Can GLP-1s Cause Depression? Examining the Signal
FDA and EMA investigations, FAERS data, WHO database analysis, and controlled studies on semaglutide and mental health. The complete picture with sources.
GLP-1s for Binge Eating Disorder
Can Ozempic help binge eating disorder? The research on GLP-1 medications for BED and compulsive eating patterns.
Brain Receptor Map: Where GLP-1s Work in the Reward System
GLP-1 receptors in the VTA, nucleus accumbens, and prefrontal cortex may explain why these drugs affect cravings. A visual guide to the neuroscience.
How to Evaluate a Compounding Pharmacy for GLP-1 Medications
How to evaluate compounding pharmacies for semaglutide and tirzepatide. 503A vs 503B explained, PCAB accreditation, COA verification, FDA warning signs, and 15 questions to ask before…
Semaglutide and Cannabis Use Disorder: What the Data Shows
A study of 680,000+ patients found semaglutide users were 44-60% less likely to develop cannabis use disorder. We break down the Wang et al. 2024 findings.
GLP-1s and Chronic Pain: An Unexpected Benefit
How GLP-1 weight loss medications may improve chronic pain conditions. The obesity-pain connection, anti-inflammatory effects, and what patients report.
GLP-1s and Dementia: The EVOKE Story and What Comes Next
Observational data suggested GLP-1s might prevent dementia. The EVOKE trial tested this directly—and failed. Here's what happened and why hope remains.
GLP-1s for Cocaine Addiction: What Early Research Shows
Semaglutide reduced cocaine self-administration by 26% in rats and cocaine-seeking by 62%. We analyze the University of Gothenburg study and $2.7M UTHealth trial.
GLP-1 and Bone Density: Does Rapid Weight Loss Put Your Skeleton at Risk?
Rapid weight loss reduces bone density, but major GLP-1 trials show no increase in fracture events. The SELECT trial, AAOS 2026 data, and what the evidence actually says about bone health…
GLP-1s and Cannabis: 44% Reduction in Use
A 2024 study found 44% lower cannabis use among patients on GLP-1 medications. What the research shows about marijuana, dopamine, and these drugs.
From Secret Shame to Prime Time
When Oprah and other celebrities started talking openly about weight loss medications, the conversation changed. The cultural shift from secret shame to mainstream acceptance.
Is Compounded Semaglutide Safe?
The truth about compounded GLP-1 medications. What we know about safety, quality concerns, and how to minimize risk.
GLP-1s for Cocaine & Stimulant Addiction
Emerging research on semaglutide for cocaine and stimulant use disorders. What the science shows and what trials are underway.
Counterfeit GLP-1 Medications
Fake Ozempic and Wegovy are circulating. How to identify counterfeit GLP-1 medications and protect yourself from dangerous fakes.
Bodybuilders on GLP-1s: The Muscle Preservation Challenge
Can you use Ozempic or tirzepatide while preserving muscle? Body composition data, cutting phase strategies, and what bodybuilders need to know about GLP-1s.
GLP-1s for Cancer Survivors: What You Need to Know
Can cancer survivors safely use Ozempic or Wegovy? Evidence on GLP-1s after cancer treatment, weight management, and special considerations for cancer history.
GLP-1s and Cirrhosis: A Complicated Question
GLP-1s show promise for fatty liver, but what about cirrhosis? Evidence, safety concerns, and why advanced liver disease requires special consideration.
GLP-1s and Your Brain: How These Drugs Get Into Your Head
GLP-1 medications access your brain directly. Understanding how they cross the blood-brain barrier explains appetite control, food noise reduction, and potential effects on addiction and…
GLP-1 Benefits Even Without Weight Loss: The Evidence Explained
New evidence shows GLP-1 medications reduce inflammation and improve organ health even before the scale moves.
GLP-1 and Bone Density: What the Longitudinal Data Actually Shows
STEP-1 DEXA substudy found -1.4% hip BMD vs. -0.5% placebo at 68 weeks. Tirzepatide showed -0.4% despite greater weight loss. A systematic review of what t
GLP-1 and Cancer Risk: The Epidemiological Evidence (Positive and Concerning)
GLP-1 and Cancer Risk: The Epidemiological Evidence (Positive and Concerning)
GLP-1 Cardiovascular Outcomes Trials: SELECT, FLOW, and What Came After
SELECT: 20% MACE reduction in non-diabetic obesity (HR 0.80). FLOW: 24% composite kidney endpoint reduction, stopped early for overwhelming benefit. SURPAS
GLP-1 Brain Imaging Studies: What fMRI and PET Scans Actually Show
Neuroimaging studies reveal how semaglutide and tirzepatide alter brain reward circuitry, appetite centers, and food cue responses. Every published study compiled.
GLP-1 in 5 Minutes: Everything You Need to Know
The quick primer on GLP-1 medications. What they are, how they work, and whether they
GLP-1 Nausea: 8 Ways to Beat It
Practical solutions for GLP-1 nausea. What causes it, when it improves, and 8 strategies that actually work.
GLP-1 Provider Red Flags: What to Watch For
How to spot sketchy GLP-1 telehealth providers. Red flags, warning signs, and what legitimate providers do differently.
The GLP-1 Starter Checklist: Everything to Have Ready
Your complete prep list before starting GLP-1 treatment. Documents, supplies, questions to ask, and how to set yourself up for success.
GLP-1 Constipation: Solutions That Actually Work
Practical fixes for GLP-1-related constipation. Why it happens and what to do about it.
What Disqualifies You From GLP-1? (And What Doesn't)
GLP-1 eligibility explained. BMI requirements, medical conditions, and common myths busted. Find out if you qualify.
GLP-1s for Alcoholism: What the JAMA Study Actually Found
The first randomized controlled trial of semaglutide for alcohol use disorder is here. We break down exactly what the February 2025 JAMA Psychiatry study found.
Food Noise Explained: What Brain Scans Actually Show
fMRI brain imaging reveals how GLP-1 medications reduce food cravings and intrusive food thoughts. Primary research from Nature Medicine and clinical trials.
GLP-1s and Anhedonia: The Pleasure-Killing Concern
If GLP-1s dampen the reward system, could they reduce pleasure from everything—not just food and drugs? What we know about anhedonia risk.
GLP-1 Drugs and Alzheimer's: Why the Largest Trials Failed Despite Promising Signs
The EVOKE trials testing semaglutide for Alzheimer's disease failed their primary endpoints in November 2025. But the story isn't that simple—and researchers haven't given up.
Alcohol and GLP-1s: What the Research Actually Says
Can you drink alcohol on Ozempic or Zepbound? The science on GLP-1 alcohol interactions: hypoglycemia risk, slower metabolism, reduced cravings, and liver protection research.
GLP-1s and Atrial Fibrillation: Weight Loss for Heart Rhythm
Weight loss reduces AFib burden significantly. How GLP-1 medications may help atrial fibrillation through weight loss and beyond.
FLOW Trial: Semaglutide for Chronic Kidney Disease
Evidence review of the FLOW trial of semaglutide for diabetic chronic kidney disease.
GLP-1s and Alcohol: The JAMA Study
A major JAMA Psychiatry study found 50-56% lower alcohol use disorder among GLP-1 patients. The science behind why Ozempic makes people drink less.
Four New GLP-1 Agents Approved or Approaching Market in 2026
Foundayo, Ozempic tablets, CagriSema, Wegovy 7.2mg — the options are expanding faster than ever.
The Anhedonia Question
Some people report reduced enjoyment of food, hobbies, and life on GLP-1 medications. What does the science say about this concern?
Athletes and GLP-1s: What You Need to Know
How Ozempic and Wegovy affect athletic performance, muscle mass, endurance, and recovery. WADA status, professional athlete considerations, and sports-specific guidance.
GLP-1 Anti-Inflammatory Effects: The Evidence Beyond Weight Loss
Meta-analysis of 40 RCTs: GLP-1 drugs significantly reduce CRP and TNF-alpha vs placebo and other diabetes drugs. Only 20-60% of CRP reduction is explained by weight loss. Complete…
FLOW Trial: Semaglutide Reduced Major Kidney Disease Events by 24%
The FLOW trial is the first dedicated kidney outcomes trial for a GLP-1 drug. Semaglutide cut major kidney events by 24%, cardiovascular death by 29%, and was stopped early for efficacy.
Athletes and GLP-1s: The Complicated Intersection
Not banned by WADA, but not without controversy. From weight-class sports to marathon runners, here's what athletes need to know about Ozempic and Mounjaro.
GLP-1 for Adolescents: What STEP TEENS Showed
STEP TEENS: semaglutide produced a 17% BMI reduction in adolescents aged 12-17 with obesity. 45% dropped below the clinical obesity threshold. NEJM 2022. Complete trial data and…
The GLP-1 Affordability Transformation: Prices Fell 75%+ in 18 Months
From $1,400/month to $50-$245. How competition, policy, and oral options collapsed GLP-1 pricing.
Foundayo (Orforglipron): The First Small-Molecule GLP-1 — Complete Phase 3 Data
Foundayo (Orforglipron): The First Small-Molecule GLP-1 — Complete Phase 3 Data
GLP-1 and Addiction: The Emerging Signal From Alcohol, Nicotine, and Opioid Data
GLP-1 and Addiction: The Emerging Signal From Alcohol, Nicotine, and Opioid Data
Your First Week on GLP-1: What to Expect
Day-by-day guide to your first week on GLP-1 medication. What
All 50+ FDA Warning Letters (Sept 2025): Full Text & Analysis
The FDA sent 50+ warning letters to GLP-1 compounders in September 2025. We
EVOKE Trial Results: Semaglutide Fails Alzheimer's Test — But the Prevention Story May Be Different
Complete analysis of the EVOKE and EVOKE+ Phase 3 trials. Semaglutide didn
The Employer Health Plan Shift: Who's Still Covering GLP-1s
Analysis of employer health plan coverage for GLP-1 medications in 2026.
Fact Check: The '1 in 5 Americans on GLP-1s' Headline
The '1 in 5 Americans on GLP-1s' headline is wrong. Here's what the actual survey and claims data show about GLP-1 usage prevalence in 2026.
Fact Check: Is Compounded Semaglutide 'Just as Effective' as Wegovy?
Fact check on whether compounded semaglutide is really as effective as brand-name Wegovy.
Fact Check: 'Compounded Tirzepatide Is Illegal Now'
Fact check on the current legal status of compounded tirzepatide post-shortage.
Fact Check: Claims About GLP-1 and Alcohol Use Disorder
Fact check on GLP-1 medications for alcohol use disorder — what evidence supports the claim.
Fact Check: The Viral 'GLP-1 Birth Defect' Story
Fact check on GLP-1 birth defect claims circulating on social media.
Fact Check: GLP-1 'Muscle Loss' Claims vs. Clinical Evidence
Fact check on GLP-1 muscle loss claims versus the actual body composition trial data.
Fact Check: Do GLP-1s Cause Thyroid Cancer?
Fact check on the GLP-1 thyroid cancer black box warning and actual human risk data.
Fact Check: Is Oral Wegovy as Effective as the Injection?
Fact check comparing oral Wegovy to injectable Wegovy for weight management.
Fact Check: The 'Ozempic Face' Phenomenon
'Ozempic face' is a real phenomenon but not unique to Ozempic. Here's what dermatology literature actually says about facial changes after significant weight loss.
Fact Check: Does Zepbound Really Outperform Wegovy by 47%?
Fact check of the SURMOUNT-5 head-to-head trial comparing tirzepatide to semaglutide.
Why the FDA Removed Semaglutide From Shortage and What Happened Next
Full timeline of how the FDA ended the semaglutide and tirzepatide shortages and reshaped the GLP-1 market.
Inside the FDA's March 2026 Warning Letters to 30 Compounded GLP-1 Telehealth Companies
On March 3, 2026, the FDA issued 30 warning letters to compounded GLP-1 telehealth operators. Inside the filings: what was alleged, who responded, and what it means for patients.
EMA Safety Review: GLP-1 Drugs and Mental Health
In 2023, the EMA launched a safety review of GLP-1 drugs and suicidal ideation. In 2024, they concluded: no causal link found. Here
The 455 Adverse Event Reports: What the FDA Compounded GLP-1 Data Actually Says
The FDA cites 455+ adverse events from compounded semaglutide. What do the reports actually show? We source the data and provide context.
FDA's 503B Bulks List Proposal: A Sourced Analysis
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from 503B compounding. Every claim sourced from the Federal Register and FDA statements.
FDA Semaglutide Shortage Resolved: What It Means for Compounded GLP-1s in 2026
The FDA resolved the semaglutide shortage in February 2025. Here
ESSENCE Trial: Semaglutide Resolved Fatty Liver Disease in 62.9% of Patients
The Phase 3 ESSENCE trial showed semaglutide 2.4 mg resolved MASH in 62.9% of patients and improved liver fibrosis in 37%. Published in NEJM April 2025. FDA granted Priority Review for this…
FDA Warning Letters to GLP-1 Compounders: What Patients Need to Know
The FDA issued 80+ warning letters to GLP-1 compounders in 2025-2026. What the letters say, who was targeted, and what it means for your treatment.
Elecoglipron, CagriSema, and the Expanding GLP-1 Pipeline
The GLP-1 pipeline in mid-2026 is the most active in the drug class's history. Multiple new agents are either recently approved, awaiting FDA decision, or advancing through late-stage…
ENDO 2026: Fertility, Biological Aging, and Activity-Level Findings
Three threads from the Endocrine Society's 2026 meeting: semaglutide improved male sperm parameters by 18.2M/mL, GrimAge2 clock reduced by 2.4 years over 52 weeks, and physical activity…
Elecoglipron and the SOLSTICE Trial: Where the Oral Small-Molecule GLP-1 Stands
Pfizer's non-peptide oral GLP-1 candidate achieved 11.2% weight loss at 32 weeks in Phase 3 interim data. What makes it different from oral semaglutide, what the results mean, and the…
How the EMA and FDA Diverge on GLP-1 Regulation: A Comparative Review
Approval timelines, safety labeling differences (pancreatitis, thyroid C-cell), the absence of a 503B-equivalent in EU law, and how national HTA bodies lik
The June 29 Deadline: What the FDA's 503B Comment Period Means and What Comes Next
On April 30, 2026, the FDA published a proposed rule in the Federal Register that would formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public…
Celebrities Who've Confirmed GLP-1 Use (Updated List)
Which celebrities have actually admitted to using Ozempic, Wegovy, or Mounjaro? We tracked down the direct quotes — no speculation, just confirmed statements.
503A vs 503B: The Complete Framework for GLP-1 Compounding
Understanding FDA compounding designations, quality standards, and what certifications actually mean for your semaglutide or tirzepatide prescription.
Compounded GLP-1 Potency: What Testing Actually Reveals
FDA testing data, Novo Nordisk analyses, and independent assays reveal wide potency variation in compounded semaglutide—from 0% to over 120% of labeled strength.
Compounded GLP-1 Potency Variation: What Lab Testing Actually Shows
Independent lab testing of compounded semaglutide found products ranging from 42% to 170% of labeled potency. Here
Compounded vs Brand-Name: The Safety Data Compared
FDA testing found compounded semaglutide potency ranging 42-170% of labeled dose. FAERS reports 442 adverse events. Here
BALANCE Model: Medicare's GLP-1 Expansion Timeline
Complete implementation timeline for the CMS BALANCE Model and expanded Medicare GLP-1 coverage.
CagriSema: The Combination-Therapy Evidence Review
Evidence review of the CagriSema combination therapy trials and its competitive positioning vs tirzepatide.
How Compounded GLP-1 Pricing Works Post-Shortage
Current compounded GLP-1 pricing vs. brand-name cash-pay programs in 2026.
The Compounding Pharmacy Crackdown: Who's Still Operating and Why
Complete investigation into which compounding pharmacies are still legally operating post-crackdown.
CagriSema: Why Novo Nordisk Added Amylin to GLP-1 — and Got 22.7% Weight Loss
CagriSema combines semaglutide with cagrilintide (amylin analog). REDEFINE 1: 22.7% weight loss at 68 weeks, 60% lost 20%+. NDA filed December 2025. Complete data breakdown.
Best Deals on Prescription Weight Loss Meds for New Patients in 2026
Every way to save on GLP-1 weight loss medications in 2026. Brand-name pills from $149/mo, compounded injectables from $146/mo, and new savings programs.
Is Byetta Still Available in 2026? Exenatide Status & Alternatives
Byetta (exenatide) was discontinued by AstraZeneca in October 2024. A generic version exists from Amneal. Here
CagriSema & SURMOUNT-5: The Next-Gen GLP-1 Trial Results Explained
CagriSema produced 22.7% weight loss in REDEFINE 1. SURMOUNT-5 showed tirzepatide beats semaglutide head-to-head. What these trials mean for the future of obesity treatment.
503A vs. 503B: The Legal and Regulatory Distinction, Explained From Source Documents
503A and 503B were created by the Drug Quality and Security Act of 2013 after the NECC outbreak killed 64 people. A statutory comparison of the two framewo
Amycretin: Novo's Next-Gen Amylin/GLP-1 Co-Agonist — Phase 2 Data and Pipeline Position
CagriSema combines two separate molecules — semaglutide plus the amylin analog cagrilintide — in a fixed-dose combination injection. Amycretin takes the next step: it puts GLP-1 and amylin…
The Compounding Litigation Map: Every Novo Nordisk and Lilly Lawsuit Against GLP-1 Compounders
The Compounding Litigation Map: Every Novo Nordisk and Lilly Lawsuit Against GLP-1 Compounders
Danuglipron: The Rise and Fall of Pfizer's Oral GLP-1 — And What It Teaches Us
Pfizer's danuglipron was once the company's highest-profile pipeline asset — an oral small-molecule GLP-1 agonist that could have competed head-to-head with Novo Nordisk and Eli Lilly in…
The 503B Compounding Exclusion: What the FDA Comment Period Closure Means
The June 29, 2026 closure of the public comment period on FDA
ASCO 2026: What the New GLP-1 Cancer Risk Reduction Data Actually Shows
ASCO 2026 included a 1.3M-patient claims analysis showing reduced incidence of 13 obesity-associated cancers in GLP-1 users. The hazard ratio data — and th
ASCO 2026: Five Cancer Studies That Redefine What GLP-1s Can Do
Cancer prevention, improved immunotherapy outcomes, breast cancer risk reduction — ASCO 2026
Comparative Effectiveness: Semaglutide vs. Tirzepatide in Head-to-Head Trials
SURMOUNT-5 is the only randomized head-to-head trial: -20.2% vs. -13.7% body weight at 72 weeks favoring tirzepatide. The full results table, the cardiovas
CagriSema: The Cagrilintide + Semaglutide Combination That Beat Everything
CagriSema combines cagrilintide (an amylin analog) with semaglutide. REDEFINE trial data shows 22-25% weight loss at 68 weeks. Full data tables and analysis.
Combination Pipeline Census: Every GLP-1 Multi-Agonist in Phase 2 or Later
A complete census of multi-mechanism GLP-1 combinations in clinical development: dual agonists, triple agonists, and peptide combinations in Phase 2+.
The Danuglipron Exit: What Pfizer's GLP-1 Discontinuation Tells Us
Pfizer invested years in danuglipron (PF-06882961), a small-molecule oral GLP-1 receptor agonist. Then it walked away. The discontinuation is as informative as any positive trial result…
Discontinuation Statistics: Every GLP-1 Persistence Study Published 2024–2026
50-70% of GLP-1 patients discontinue within the first year. Here
503A Pharmacies: The Last Legal Pathway for Compounded GLP-1s?
If the FDA removes GLP-1s from the 503B Bulks List, 503A traditional pharmacies become the primary remaining pathway for compounded access. Here's how 503A compounding works and why it's…
The 2026 Guidelines Refresh: ADA, AACE, and Obesity Society Updates Compared
ADA, AACE, and The Obesity Society updated their obesity treatment guidelines in 2025-2026. What changed, where they agree, and where they diverge.
Semaglutide Sodium vs. Base: Why FDA Says Salt Forms Aren't the Same
Why FDA says semaglutide sodium and acetate are different active ingredients with no lawful compounding basis, what state boards ruled, and what to check.
How Semaglutide Is Made: Recombinant Yeast vs. Synthetic Peptide
Novo makes semaglutide in engineered yeast; synthetic makers build it chemically. What FDA and EMA documents say about impurities, generics and compounding.
Retatrutide Research Peptides: What FDA and Lab Testing Have Found
Retatrutide isn't approved. Here's what FDA warning letters, Lilly's lawsuits, poison centers and regulator lab tests found in grey-market vials as of Oct 2026.
How to Read a GLP-1 Trial on ClinicalTrials.gov: A STEP 1 Walkthrough
How to read a GLP-1 trial on ClinicalTrials.gov, using STEP 1: NCT numbers, primary outcomes, estimands, the results tab, and how to spot outcome switching.
Wegovy Pill Prescribing Information: The Dosing Rules That Matter
The Wegovy pill label, read for patients: empty stomach, 4-ounce water limit, 30-minute wait, the 1.5 to 25 mg dose steps, and how it differs from Rybelsus.
Mazdutide: China's Approved GLP-1/Glucagon Drug and Its US Status
Mazdutide (Xinermei) is approved in China for obesity and type 2 diabetes. GLORY and DREAMS trial data, the US Phase 2, and why it isn
Foundayo (Orforglipron) Prescribing Information, Read for Patients
What the Foundayo label says: the April 2026 approval, dose steps from 0.8 to 17.2 mg, no food rules, the boxed warning, and interactions that change dosing.
Generic Semaglutide in Canada, India, Brazil and China: 2026 Status
Where generic semaglutide is sold in 2026: Canada, India and Brazil launch dates, prices where reported, China
FDA Import Alert 66-80: Where Compounders' Semaglutide API Comes From
Compounders buy raw semaglutide and tirzepatide from ingredient manufacturers, many of them overseas, and since September 2025 FDA has controlled that flow with Import Alert 66-80, a "green…
How to Check FDA's Drug Shortage Database for GLP-1s Yourself
FDA's Drug Shortages database is a free public lookup, and a single word in it, "Resolved," is what ended the legal basis for mass-compounded copies of semaglutide and tirzepatide. As of…
Certificate of Analysis for Compounded Semaglutide: How to Read It
How to read a certificate of analysis for compounded semaglutide or tirzepatide: identity, potency, purity, endotoxin, sterility, and what to ask your pharmacy.
Compounded GLP-1 Dosing Errors: Units vs. mL in FDA's Own Reports
FDA found patients injecting 5 to 20 times their compounded semaglutide dose. Here
How to Spot Red Flags in an Online GLP-1 Offer
Scout Theory Editorial · Updated October 19, 2026 · Educational, not medical advice
Petrelintide, Eloralintide and the Amylin Pipeline After CagriSema
Eloralintide, petrelintide and cagrilintide alone are in Phase 3. Their Phase 2 weight loss, side effects and trial timelines, read from primary sources.
China's GLP-1 Wave: Ecnoglutide, Semaglutide Copies and US Prices
Ecnoglutide is now approved in China, semaglutide copies are coming, and Hengrui
Compounded GLP-1: Seven Questions About Pharmacy and Legal Status
Scout Theory Editorial · Updated October 19, 2026 · Educational, not medical advice
ACHIEVE: The Type 2 Diabetes Filing Nobody Is Watching
Eli Lilly plans a type 2 diabetes application for orforglipron based on the phase 3 ACHIEVE program. What is known about the program and why the indication matters.
The Compounding Wind-Down: Every Deadline, in Order
A complete dated timeline of the GLP-1 compounding wind-down, from 2022 shortage status through the FDA
22,966 Cases: The Poison Center Record on GLP-1 Exposures, 2019–2025
A 1,500% increase in call volume, mostly accidental therapeutic errors, and one failure mode specific to compounded products. What this dataset supports and what it does not.
Gastric Emptying, Surgery, and Aspiration: What the Evidence Actually Supports
What the evidence supports on GLP-1 receptor agonists, delayed gastric emptying, and pulmonary aspiration risk during anaesthesia — including the FDA-required study.
Foundayo's Postmarketing Requirements, Decoded
A reading of the postmarketing requirements in the FDA approval letter for Foundayo (orforglipron), including the 15-year MTC registry and aspiration study.
What a National Priority Voucher Actually Does
Foundayo was the fifth approval under a pilot program most people have never heard of, and the first new molecular entity. The program's own eligibility rules were still under public…
The GLP-1 Litigation Docket: Case Tracker, September 2026
A September 2026 status tracker of GLP-1 litigation: Lilly v. Empower, Lilly v. Strive, the Strive antitrust dismissal, Novo v. Hims, and telehealth suits.
50 Days: How Foundayo Became the Fastest New Drug Approval Since 2002
Foundayo was approved 50 days after filing and 294 days ahead of its PDUFA date — the fastest new molecular entity approval since 2002. How it happened.
ATTAIN-1 and ATTAIN-2: The Trials Behind the Foundayo Approval
A breakdown of the ATTAIN-1 and ATTAIN-2 trials supporting FDA approval of orforglipron (Foundayo), including efficacy, adverse events, and study limits.
The 503B Bulks List Proposed Rule, Annotated
On April 30, 2026 the FDA moved to strip semaglutide, tirzepatide, and liraglutide of the regulatory status that made mass compounding lawful. This is what the proposal does, which…
Published Cost-Effectiveness Studies on GLP-1s: What ICER Actually Concluded
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
Judge Pittman's Full Ruling in OFA v. FDA: The Legal Text That Reshaped Compounding
Judge Mark Pittman's ruling in the Outsourcing Facilities Association v. FDA cases became the pivot point for compounded GLP-1 legal ground. Here's what the ruling actually said, translated…
GLP-1 Discontinuation Weight Regain Studies: The 12-Month Follow-Up Data
What the 12-month follow-up studies on GLP-1 discontinuation actually show about weight regain patterns.
FAERS Data on GLP-1 Adverse Events: A Patient's Guide to the Reporting Database
How to read the FDA Adverse Event Reporting System (FAERS) data on GLP-1s — what the numbers actually mean and their limits as a signal.
What the 2026 ADA Consensus Statement Says About GLP-1s in Type 2 Diabetes
The 2026 American Diabetes Association consensus statement on GLP-1s in type 2 diabetes management — what changed and what it recommends.
Reading the WHO 2026 Obesity Guidance: What Changed and Why
The WHO 2026 obesity guidance update — what changed from prior versions, what the new recommendations actually say about GLP-1s, and how they
The MASH Data on Tirzepatide: SYNERGY-NASH Results Explained
The SYNERGY-NASH trial results on tirzepatide for metabolic dysfunction-associated steatohepatitis — what the data showed and what it means for MASH treatment.
Reading the STEP-HFpEF Follow-Up: Semaglutide in Heart Failure
The STEP-HFpEF follow-up data on semaglutide for obese patients with heart failure with preserved ejection fraction — what changed and what the data means.
Semaglutide + SGLT2 Inhibitors: The Combination Trial Landscape in 2026
The 2026 evidence landscape for combining semaglutide with SGLT2 inhibitors — trials, subgroup data, and what combining the two classes actually delivers.
The Retatrutide Phase 3 Interim: What the 2026 Readout Actually Showed
Retatrutide's Phase 3 program has generated interim data through 2026 pointing toward one of the largest pharmacologic weight loss magnitudes yet demonstrated. Here's what the interim…
Reading Novo Nordisk's Q2 2026 Earnings Call: What Investors Learned About Wegovy
Public company earnings calls are unfiltered windows into how manufacturers see their own products. Novo Nordisk's Q2 2026 call carried substantive discussion of Wegovy trajectory — volume…
The GLP-1 Pancreatitis Signal: What the 2026 Meta-Analyses Say
The 2026 meta-analyses on GLP-1s and pancreatitis risk — what the pooled data shows, how it changes over follow-up, and what the label language reflects.
The FLOW Kidney Trial Follow-Up: What Semaglutide Delivered for CKD Patients
FLOW established semaglutide as the first GLP-1 with a clear kidney-protection indication in adults with type 2 diabetes and chronic kidney disease. Follow-up data has extended the picture…
SURMOUNT-MMO Long-Term Follow-Up: Where Tirzepatide Cardiovascular Outcomes Stand
Tirzepatide's cardiovascular outcome story has expanded meaningfully in 2026 as long-term SURMOUNT-MMO follow-up data has become available. Here's what the trial actually established, what…
The Full Text of Novo Nordisk's Recent Warning Letters, Read for Patients
Novo Nordisk's outbound legal correspondence to compounders and telehealth marketers is generally not made public in full text, but sample letters and pleadings from resulting litigation…
Telogen Effluvium and Rapid Weight Loss: Mechanisms and Published Case Data
A review of what the dermatology literature establishes about diffuse hair shedding after rapid weight loss, and how it applies to GLP-1 therapy.
The Placebo Arms Tell a Story: What Control Groups Reveal About Lifestyle-Only Loss
Reading the placebo arms of the major GLP-1 obesity trials as evidence in their own right about what structured lifestyle intervention produces.
GLP-1s in Adults Over 65: Efficacy and Safety Signals From Subgroup Analyses
What age-stratified subgroup analyses of the major GLP-1 trials report about efficacy and safety in older adults, and where the evidence thins out.
Lean Mass Changes on GLP-1 Therapy: A Review of DEXA Data Across Trials
What body-composition substudies using DEXA actually measured about fat mass and lean mass during semaglutide and tirzepatide treatment.
Maintenance-Phase Dosing Research: Evidence Behind Lower-Dose Continuation
A review of what trial evidence exists — and mostly does not exist — for continuing GLP-1 therapy at a reduced maintenance dose after weight loss.
GLP-1s and Hepatic Outcomes: The MASLD Evidence Base Through Mid-2026
A review of the trial evidence linking GLP-1 receptor agonists to steatotic liver disease outcomes, including the ESSENCE results and their limits.
Gallbladder Events in GLP-1 Trials: Incidence Data and Risk Interpretation
A review of the trial and meta-analytic evidence on gallbladder and biliary disease during GLP-1 receptor agonist therapy, and how to separate drug effect from weight-loss effect.
GLP-1 Adherence Research: Why Patients Discontinue and What Predicts Persistence
A review of real-world claims and pharmacy data on GLP-1 persistence, the reasons patients stop, and why trial adherence and real-world adherence diverge.
Dose-Response Relationships in Semaglutide Trials: What Each Milligram Buys
A review of the randomized dose-ranging evidence for semaglutide, including where the efficacy curve flattens and where the tolerability curve steepens.
Appetite, Reward, and fMRI: What Imaging Studies Show GLP-1s Do in the Brain
A review of the neuroimaging literature on GLP-1 receptor agonists, food cue reactivity, and the mechanisms behind reduced
Compounded Semaglutide Quality Studies: What Independent Testing Published in 2025–2026 Found
A review of the published analytical testing, regulatory reporting and adverse-event data on compounded semaglutide preparations, and what remains unmeasured.
Discontinuation Outcomes in GLP-1 Trials: What Extension Studies Show About Weight Regain
A review of the randomized withdrawal and extension data on what happens to body weight after semaglutide and tirzepatide are stopped.
GLP-1 Medications and the Brain: The Emerging Neurodegeneration Data
GLP-1 receptors are expressed throughout the brain. Emerging evidence suggests neuroprotective effects in Alzheimer
FLOW Trial Deep Dive: Semaglutide's 24% Kidney Disease Risk Reduction
Complete analysis of the FLOW trial: semaglutide reduced major kidney events by 24%, CV events by 18%, and death by 20% in T2D patients with CKD. Full data and methodology.
Medicare GLP-1 Coverage Economics: What the $50 Copay Actually Means
The Medicare GLP-1 Bridge program ($50/month copay, July 2026) represents the largest government investment in obesity pharmacotherapy. Cost-benefit analysis with CBO projections and…
GLP-1 Medications and Breast Cancer: The Emerging Protective Signal
Emerging May 2026 data suggests GLP-1 medications may be associated with improved breast cancer outcomes. Observational evidence, biological rationale, and research limitations assessed.
GLP-1 Insurance Coverage in 2026: What's Changed and What to Expect
GLP-1 insurance coverage timeline 2026: Medicare Bridge $50/month copay, Medicaid expansion, commercial plan trends, and the prior authorization playbook.
TRIUMPH-1 Phase 3 Topline Results: Retatrutide Achieves 28.3% Weight Loss at 80 Weeks
Full analysis of TRIUMPH-1 Phase 3 topline data: retatrutide 4mg/9mg/12mg efficacy, cardiometabolic outcomes, safety signals, and regulatory timeline.
Survodutide: Boehringer Ingelheim's GLP-1/Glucagon Dual Agonist
Survodutide combines GLP-1 and glucagon receptor agonism. Phase 3 data expected 2026. Positioned between tirzepatide and retatrutide. Complete compound profile.
Retatrutide vs. Tirzepatide vs. Semaglutide: Phase 3 Efficacy and Safety Data Compared
Cross-trial comparison of retatrutide (TRIUMPH-1), tirzepatide (SURMOUNT-1), and semaglutide (STEP-1) Phase 3 data. Efficacy, safety, and cardiometabolic outcomes.
The Oral GLP-1 Landscape in 2026: Three Drugs, Three Strategies, One Goal
Oral semaglutide, orforglipron (Foundayo), and amycretin compared. Efficacy, pricing, mechanism, and what the pill revolution means for GLP-1 access.
Pemvidutide: The Muscle-Sparing Dual Agonist With MASH Breakthrough Designation
Pemvidutide is a GLP-1/glucagon dual agonist developed by Altimmune that received FDA Breakthrough Therapy designation for MASH in January 2026. Its glucagon-mediated fat oxidation…
GLP-1 Safety Signals in 2026: A Comprehensive Evidence Review
Complete review of GLP-1 safety signals: pancreatitis, thyroid cancer, gastroparesis, NAION, hair loss, ED, and gallbladder events. Evidence quality assessed.
GLP-1 Market Intelligence: Tirzepatide Projected as World's Top-Selling Drug in 2026
Tirzepatide projected at $45B in 2026 sales. Semaglutide at $39.5B. Market analysis of the $84.5B GLP-1 pharmaceutical landscape.
GLP-1 Manufacturing at Scale: How Lilly and Novo Are Meeting Demand in 2026
Both Eli Lilly and Novo Nordisk have committed billions to GLP-1 manufacturing expansion. How the production scale-up is progressing, what it means for supply and pricing, and the…
GLP-1 Muscle Loss: What the 2026 Data Actually Shows
Three major 2026 publications reframe the GLP-1 muscle loss debate: relative muscle mass improves, liver mass loss exceeds muscle loss, and mitochondrial proteins increase. Evidence-based…
What Happens When You Stop GLP-1 Medications: The Weight Regain Data
STEP-1 extension data: two-thirds of weight regained within 1 year of stopping semaglutide. Cardiometabolic improvements reversed proportionally. Evidence-based discontinuation analysis.
Compounded Semaglutide Stability: What the Chemistry Says
Compounded semaglutide stability: beyond-use dating requirements, peptide degradation pathways, storage conditions, and why 503B outsourcing facilities provide more reliable stability data…
GLP-1 Medications and Addiction: The Unexpected Data on Alcohol, Nicotine, and Substance Use
GLP-1 medications reduce alcohol cravings by 41%, decrease smoking urge, and show signals across multiple substance use disorders. Complete evidence review.
FDA Compounding Enforcement 2026: What's Actually Happening to 503A/503B Pharmacies
FDA GLP-1 compounding enforcement actions in 2026. Warning letters, 503A vs 503B legal status, shortage declarations, and which pharmacies are still operating legally.
CagriSema: Novo Nordisk's Next-Generation GLP-1/Amylin Combination
CagriSema combines semaglutide with cagrilintide (amylin analog). Phase 3 results expected 2026, targeting ~25% weight loss. Full mechanism and trial analysis.
BELIEVE Trial: Bimagrumab + Semaglutide Achieves 22.1% Weight Loss With 92.8% From Fat Mass
The BELIEVE trial (NCT05616013), published in Nature Medicine March 2026, is the first randomized trial to demonstrate pharmacological muscle preservation during GLP-1 therapy. 507…
FDA's 503B Exclusion: The April 2026 Move That Ends Large-Scale GLP-1 Compounding
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Here
The Ozempic Plateau: Why Weight Loss Stalls and What the Data Says to Do About It
GLP-1 weight loss plateaus are normal and documented in every major trial. Here
GLP-1 and Smoking Cessation: What Semaglutide Could Mean for Quitting
222,942-patient study shows semaglutide users have 32% fewer tobacco-related medical encounters. Active trials, the dopamine mechanism, and what it means for smokers.
GLP-1 Medications and Testosterone: What the Clinical Evidence Shows
Systematic reviews confirm GLP-1 drugs increase testosterone in obese men by 1.39 ng/mL on average. How it works, fertility implications, and every major study explained.
Who Qualifies for GLP-1 Medications? Complete Eligibility Criteria for 2026
Complete GLP-1 eligibility guide: BMI requirements, qualifying conditions, Medicare coverage starting July 2026, insurance criteria, and who does not qualify. Every threshold explained with…
GLP-1 Medications and Depression: What 100,000 Patients Tell Us
Does semaglutide help or worsen depression? A 100,000-person Swedish study, FDA safety reviews, and every major finding on GLP-1 medications and mental health — sourced and explained.
Retatrutide Phase 3 Results: 28.7% Weight Loss with Triple Agonist
On December 11, 2025, Eli Lilly announced the first Phase 3 results for retatrutide—a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon simultaneously. The…
Retatrutide: The "Triple G" Drug Showing 28.7% Weight Loss
If tirzepatide (Zepbound/Mounjaro) was a leap forward with its dual hormone action, retatrutide is aiming for a triple jump. Eli Lilly's newest weight loss candidate targets not two, but…
SELECT Trial: Wegovy Reduces Heart Attacks and Strokes by 20%
The SELECT trial proved semaglutide reduces cardiovascular events in people without diabetes. Full analysis of the landmark study that changed GLP-1 treatment.
JAMA 2025: Semaglutide Reduces Alcohol Consumption in First Randomized Trial
The first placebo-controlled trial of semaglutide for alcohol use disorder shows reduced drinking, cravings, and heavy drinking days. Full study breakdown.
FDA Approves Semaglutide for MASH: The ESSENCE Trial Results
Wegovy becomes the first GLP-1 approved for fatty liver disease (MASH). ESSENCE trial showed 63% achieved resolution of liver inflammation vs 34% on placebo.
Semaglutide Approved for MASH: What the ESSENCE Trial Showed
FDA approves semaglutide for MASH with liver fibrosis. Breaking down the ESSENCE trial data: 63% resolution of steatohepatitis, 37% fibrosis improvement.
GLP-1 Side Effects Timeline: Week-by-Week What to Expect
A week-by-week guide to Ozempic and Wegovy side effects. When nausea peaks, when it fades, and what symptoms warrant calling your doctor.
Orforglipron: The Daily Oral GLP-1 Pill That Could Change Everything
Imagine taking a GLP-1 medication as a simple daily pill—no injections, no refrigeration, taken anytime without food or water restrictions. That's exactly what Eli Lilly's orforglipron…
"Ozempic Babies": How GLP-1s Affect Fertility and Birth Control
When GLP-1 medications were approved for weight loss, something unexpected followed: stories of surprise pregnancies. Women who had struggled with infertility for years reported becoming…
"Ozempic Babies": The Fertility Surprise Explained
Why women on GLP-1 medications are reporting unexpected pregnancies. The science behind fertility restoration, birth control absorption, and what you need to know.
"Ozempic Babies": The Fertility Surprise Explained
Why are women getting pregnant on Ozempic? We explain the science behind restored fertility, birth control concerns, and what the research shows.
"Ozempic Face": Why Weight Loss Can Age Your Face and What You Can Do
Ozempic face refers to facial sagging and hollowing from rapid weight loss. Here
Loose Skin After GLP-1 Weight Loss: What to Realistically Expect
You've probably heard of "Ozempic face." Maybe also "Ozempic butt." These viral terms describe the loose, sagging skin that can result from rapid weight loss on GLP-1 medications. It's a…
Ozempic Approved for Kidney Disease: The FLOW Trial Breakthrough
FDA approves semaglutide for chronic kidney disease in type 2 diabetes. FLOW trial showed 24% reduced risk of kidney failure. Full trial analysis.
Why Ozempic Doesn't Work for Everyone: The Non-Responder Problem
GLP-1 medications have been called "game-changers" for weight loss. And for many people, they are. But here's what often gets buried under the headlines: not everyone responds to these…
Ozempic Side Effects Timeline: Week-by-Week What to Expect
A week-by-week guide to GLP-1 side effects. When nausea starts, peaks, and resolves. When to call your doctor. What
The Ozempic Thyroid Cancer Warning: What the Black Box Actually Means
GLP-1 medications carry a black box warning for thyroid cancer based on rodent studies. Here
The Ozempic Plateau: Why Weight Loss Stalls and What Actually Works
Weight loss plateaus on GLP-1 medications are normal, typically hitting around week 60. Here
How Much Protein Do You Need on GLP-1 Medications?
Protein requirements on Ozempic and Wegovy: research-based recommendations, how to hit targets when appetite is suppressed, and why it matters for muscle.
Zepbound Becomes First FDA-Approved Drug for Sleep Apnea
On December 20, 2024, the FDA approved Zepbound as the first-ever medication for obstructive sleep apnea. Here
GLP-1 Compounding Legal Status: What's Actually Legal Now
The FDA declared semaglutide and tirzepatide shortages resolved. Here
GLP-1 Timeline: Every FDA Approval from 2005 to Today
Complete chronological history of GLP-1 medication FDA approvals. From Byetta (2005) to today